Advertisement

Sodium Channel Antagonists

  • Katherine D. TravnicekEmail author
Chapter

Abstract

Voltage-gated sodium channels (Nav) that initiate electrical signals in excitable nerve and muscle cells are molecular targets for drugs and acquire disease mutations. These ion channels were first discovered in 1952 by researchers Hodgkin and Huxley who published landmark papers in The Journal of Physiology. The three key features of sodium channels discovered were voltage-dependent activation, rapid inactivation, and selective ion conductance. Since that time, a total of nine sodium channels have been discovered. The Nav isoforms of most interest as analgesic targets are Nav 1.3, Nav 1.7, Nav 1.8, and Nav 1.9 as they play specific roles in the neurobiology of pain and serve as potential analgesic targets. Knowledge of these channels’ structure and function, as well as their alterations in chronic pain, are vital to understanding how current sodium channel antagonists work but also for future drug developments. Currently, sodium channel antagonists fall into four pharmacological classes including anti-arrhythmics, anticonvulsants, local anesthetics, and antidepressants (discussed in another chapter). The sodium channel antagonists discussed in this chapter are considered nonselective.

Keywords

Sodium channel antagonists Sodium channel blockers Sodium channels Neuropathic pain Local anesthetics Anticonvulsants Theories of anesthetic action Anti-arrhythmics Mexiletine 

Recommended Reading

  1. 1.
    Akopian AN, et al. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379:257–62.CrossRefGoogle Scholar
  2. 2.
    Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, et al. The tetrodotoxin resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci. 1999;2:541–8.CrossRefGoogle Scholar
  3. 3.
    Cao L, Nitzsche N, McDonnell A, Alexandrou A, Saintot P-P, Loucif AJC, Brown AR, Young G, Mis M, Randall A, Waxman SG, Stanley P, Kirby S, Tarabar S, Gutteridge A, Butt R, McKernan RM, Whiting R, Ali Z, Bilsland J, Stevens EB. Pharmacological reversal of pain phenotype in iPSC-derived sensory neurons and human subjects with inherited erythromelalgia. Sci Transl Med. 2016;8(335):335ra56. PMID: 27099175 (first demonstration of proof-of-principle that Nav1.7 blocker can attenuate pain in humans).CrossRefGoogle Scholar
  4. 4.
    Cummins TR, Waxman SG. Down regulation of tetrodotoxin-resistant sodium currents and up-regulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. iJ Neurosci. 1997;17:3503–14.CrossRefGoogle Scholar
  5. 5.
    Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN, Waxman SG. A novel persistent tetrodotoxin-resistant sodium current in small primary sensory neurons. J Neurosci. 1999;19:RC43.CrossRefGoogle Scholar
  6. 6.
    de León-Casasola OA, Mayoral V. The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence. J Pain Res. 2016;12(9):67–79.  https://doi.org/10.2147/JPR.S99231. eCollection 2016.CrossRefGoogle Scholar
  7. 7.
    Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain. 2006;7(Suppl 1):S3–S12.CrossRefGoogle Scholar
  8. 8.
    Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Ann Rev Neurosci. 2010;33:325–47. PMID: 20367448 (Overview of Na channels in pain).CrossRefGoogle Scholar
  9. 9.
    Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The NaV1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013;14(1):49–62. PMID: 23232607 (the most complete review on Nav1.7 and pain).CrossRefGoogle Scholar
  10. 10.
    Dib-Hajj SD, Black JA, Waxman SG. NaV1.9: a sodium channel linked to human pain. Nat Rev Neurosci. 2015;16:511–9. PMID 26243570 (the most complete review on Nav1.9 and pain).CrossRefGoogle Scholar
  11. 11.
    Faber CG, Lauria G, Merkies ISJ, Cheng X, Han C, Ahn H-S, Persson A-K, Hoeijmakers JGJ, Gerrits MM, Pierro T, Lombardi R, Kapetis D, Dib-Hajj SD, Waxman SG. Gain-of-function NaV1.8 mutations in painful neuropathy. Proc Natl Acad Sci. 2012;109:19444–9. PMID: 23115331.CrossRefGoogle Scholar
  12. 12.
    Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.CrossRefGoogle Scholar
  13. 13.
    Geha P, Yang Y, Estacion M, Schulman BR, Tokuno H, Apkarian AV, Dib-Hajj SD, Waxman SG. Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling. JAMA Neurol. 2016;73(6):659–767.  https://doi.org/10.1001/jamaneurol.2016.0389. PMID: 27088781. (first study using pharmacogenomics to treat patients in a personalized, "precidion": manner with a Na channel blocker).CrossRefPubMedGoogle Scholar
  14. 14.
    Han C, Huang J, Waxman SG. Sodium channel NaV1.8: emerging links to human disease. Neurology. 2016;86:473–83. PMID 26747884.CrossRefGoogle Scholar
  15. 15.
    Levinson SR, et al. The role of sodium channels in chronic pain. Muscle Nerve. 2012;46(2):155–65.CrossRefGoogle Scholar
  16. 16.
    Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain. 2000;87(1):7–17.CrossRefGoogle Scholar
  17. 17.
    Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10(7):685–92.CrossRefGoogle Scholar
  18. 18.
    Sidhu HS, Sadhotra A. Current status of the new antiepileptic drugs in chronic pain. Front Pharmacol. 2016;7:276.  https://doi.org/10.3389/fphar.2016.00276. Published online 2016 Aug 25. PMCID: PMC4996999.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J Pain Symptom Manag. 2017;53:614–29.CrossRefGoogle Scholar
  20. 20.
    Tan A, Samad O, Dib-Hajj SD, Waxman SG. Virus-mediated knockdown of Nav1.3 in dorsal root ganglia of STZ-induced diabetic rats alleviates tactile allodynia. Mol Med. 2015;21:544–52. PMID 26101954.CrossRefGoogle Scholar
  21. 21.
    Tremont-Lukats IW, Challapalli V, McNicol ED, et al. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005;101:1738–49.CrossRefGoogle Scholar
  22. 22.
    Wood JN, et al. Voltage-gated sodium channels and pain pathways. J Neurobiol. 2004;61(1):55–71.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pain Institute of NevadaLas VegasUSA

Personalised recommendations